We at AOP Orphan are European pioneers in the field of rare diseases, researching, developing, producing, and distributing innovative solutions worldwide since 1996. Learn more about the company here.
We at AOP Orphan focus on rare and special diseases particularly in the areas of HematoOncology, Cardiology & Pulmonology, Neurology & Metabolic Disorders and Intensive Care. Learn more about the indications, its symptoms, diagnosis, therapies and everyday life here.
Our strategic goal at AOP Orphan is to constantly deliver new treatment options for the patients with rare disease. Learn more about the current product portfolio and countries' availability here.
Agile, ambitious and aligned team members, mutual appreciation and commitment - this is what makes AOP Orphan a successful company and great place to work. Learn more about the company, open positions and everyday life at AOP Orphan here.
"Introducing treatments to the Nordic market is a complex task we are eager to master for the benefit of patients!“
Bettina Blosse | Managing Director Nordic Countries
Silver Export Award presented to AOP Orphan
AOP Orphan reports full validity of arbitral award against PharmaEssentia
Health Europe: AOP Orphan a European pioneer in the field of rare and complex diseases
ESC Congress 2021
ERS International Congress 2021
AOP Orphan team covers all essential aspects of product development, starting with preclinical research & toxicology, extending to pharmaceutical & clinical development, including regulatory affairs, quality management & pharmacovigilance.
Partnering is of key importance for AOP Orphan. It allows further developing AOP Orphan’s rare disease portfolio and enables to approach patients beyond company’s core markets in Europe.
In the field of rare diseases the AOP Orphan team develops and investigates therapy options for patients with rare diseases – commitment and appreciation are the essence of our cooperative work.